Ventum
BuyMay 8, 2026
Target: $0.50
$30.00
— (—)Oct 23, 2026, 8:00 PM ET
Market Closed
Video Interviews
View All Interviews →Company Overview
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Key Highlights
- Biotechnology · Healthcare
- Led by Aetna Wun Trombley
- 65 employees
- Based in South San Francisco, CA
Analyst Coverage
View All Coverage →Red Cloud
BuyMay 6, 2026
Target: $0.45
Beacon
Speculative BuyMay 2, 2026
Target: $0.48
Haywood
BuyApr 30, 2026
Target: $0.55
Economic Calendar
View more →- Oct 24
Initial Jobless Claims
8:30 AM ET
- Oct 24
GDP Growth Rate (QoQ)
8:30 AM ET
- Oct 24
Pending Home Sales (MoM)
10:00 AM ET
- Oct 24
Natural Gas Inventories
10:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
80,685 −1.27%
Stock Quote
View Full Quote →NASDAQ:LYCA
Lycia Therapeutics Inc.
$30.00
— (—)- Day Range
- $22.19 – $36.49
- 52 Week Range
- 22.19-36.4931
- Volume
- 2,280,584
- Avg. Volume
- —
- Market Cap
- 1.6B
- Shares Outstanding
- —
Market data delayed by 15 minutes.
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA, US
- Incorporated
- Oct 23, 2026
- Website
